Search

Displaying results 6391 - 6400 of 8006 in total
  1. Drug

    Fenofibrate

    go.drugbank.com/drugs/DB01039
    ApprovedInvestigational

    Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. Fenofibrate was granted FDA approval on 31 December 1993.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: FENOFIBRATO MK 100 MG
  2. Drug

    Chlorbenzoxamine

    go.drugbank.com/drugs/DB13788
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  3. Drug

    Idanpramine

    go.drugbank.com/drugs/DB13276
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  4. Drug

    TOP-1288

    go.drugbank.com/drugs/DB14839
    Investigational

    TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

  5. Drug

    Afimkibart

    go.drugbank.com/drugs/DB18718
    Investigational

    It is being investigated for ulcerative colitis.

  6. Drug

    Diethanolamine

    go.drugbank.com/drugs/DB20489
    Investigational

    Diethanolamine is under investigation in clinical trial NCT02499549 (Two Treatment Regimens of Cocamide DEA Lotion for Head Lice). Diethanolamine has a monoisotopic molecular weight of 105.08 Da.

  7. Drug

    Xelaglifam

    go.drugbank.com/drugs/DB21598
    Investigational

    Xelaglifam is under investigation in clinical trial NCT04982705 (IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics). Xelaglifam has a monoisotopic molecular weight of 501.2 Da.

  8. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. … The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.

  9. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is a fluorescent dye or luminescent agent.

  10. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral